Unknown

Dataset Information

0

Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.


ABSTRACT: Importance:In December 2013, the panel members appointed to the Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC8) published a recommendation that non-Black adults initiate antihypertensive medication with a thiazide-type diuretic, calcium channel blocker, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB), whereas Black adults initiate treatment with a thiazide-type diuretic or calcium channel blocker. ?-Blockers were not recommended as first-line therapy. Objective:To assess changes in antihypertensive medication classes initiated by race/ethnicity from before to after publication of the JNC8 panel member report. Design, Setting, and Participants:This serial cross-sectional analysis assessed a 5% sample of Medicare beneficiaries aged 66 years or older who initiated antihypertensive medication between 2011 and 2018, were Black (n?=?3303 [8.0%]), White (n?=?34?943 [84.5%]), or of other (n?=?3094 [7.5%]) race/ethnicity, and did not have compelling indications for specific antihypertensive medication classes. Exposures:Calendar year and period after vs before publication of the JNC8 panel member report. Main Outcomes and Measures:The proportion of beneficiaries initiating ACEIs or ARBs and, separately, ?-blockers vs other antihypertensive medication classes. Results:In total, 41?340 Medicare beneficiaries (65% women; mean [SD] age, 75.7 [7.6] years) of Black, White, or other races/ethnicities initiated antihypertensive medication and met the inclusion criteria for the present study. In 2011, 25.2% of Black beneficiaries initiating antihypertensive monotherapy did so with an ACEI or ARB compared with 23.7% in 2018 (P?=?.47 for trend). Among beneficiaries initiating monotherapy, the proportion filling a ?-blocker was 20.1% in 2011 and 15.4% in 2018 for White beneficiaries (P??.10 for interaction). Conclusions and Relevance:A substantial proportion of older US adults who initiate antihypertensive medication do so with non-guideline-recommended classes of medication.

SUBMITTER: Colvin CL 

PROVIDER: S-EPMC7675104 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.

Colvin Calvin L CL   King Jordan B JB   Oparil Suzanne S   Wright Jackson T JT   Ogedegbe Gbenga G   Mohanty April A   Hardy Shakia T ST   Huang Lei L   Hess Rachel R   Muntner Paul P   Bress Adam A  

JAMA network open 20201102 11


<h4>Importance</h4>In December 2013, the panel members appointed to the Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC8) published a recommendation that non-Black adults initiate antihypertensive medication with a thiazide-type diuretic, calcium channel blocker, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB), whereas Black adults initiate treatment with a thiazide-type diuretic or calcium chan  ...[more]

Similar Datasets

| S-EPMC4143342 | biostudies-literature
| S-EPMC3626354 | biostudies-literature
| S-EPMC9190066 | biostudies-literature
| S-EPMC3349013 | biostudies-literature
| S-EPMC8602956 | biostudies-literature
| S-EPMC9836959 | biostudies-literature
| S-EPMC7793388 | biostudies-literature
| S-EPMC9428741 | biostudies-literature
| S-EPMC11365002 | biostudies-literature
| S-EPMC3332042 | biostudies-literature